Systematic Review of Chinese Herbal Medicines for High-Altitude Pulmonary Diseases

This systematic review explores the role of Chinese Herbal Medicines (CHM) in managing high-altitude hypoxia-related pulmonary diseases, including high-altitude pulmonary edema, high-altitude pulmonary hypertension, and other related conditions. The authors aim to synthesize available evidence to establish a theoretical foundation for precise prevention and management of these disorders.

The review does not report pooled effect sizes, patient populations, sample sizes, or specific interventions and comparators. As a result, the findings are qualitative in nature, focusing on the potential mechanisms and theoretical benefits of CHM rather than quantitative outcomes. The absence of meta-analytic data limits the strength of conclusions.

Key limitations include unreported adverse events, serious adverse events, and discontinuation rates, making it impossible to assess the safety profile of CHM in this context. Additionally, the review does not specify the number of included studies or their quality, which undermines the reliability of the synthesized evidence.

For clinicians, this review offers a conceptual framework but does not provide actionable clinical guidance due to the lack of concrete data on efficacy, safety, and patient outcomes. Further rigorous studies with standardized protocols and outcome measures are needed before CHM can be recommended for high-altitude pulmonary conditions.